Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Revenue (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Revenue for 16 consecutive years, with $30.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue changed 0.04% to $30.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $112.8 million, a 12.61% decrease, with the full-year FY2025 number at $112.8 million, down 5.91% from a year prior.
  • Revenue was $30.6 million for Q4 2025 at Anika Therapeutics, up from $27.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $44.3 million in Q2 2023 to a low of -$2.9 million in Q4 2023.
  • A 5-year average of $31.2 million and a median of $35.1 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 107.78% in 2022, then soared 1155.61% in 2024.
  • Anika Therapeutics' Revenue stood at $35.8 million in 2021, then tumbled by 107.78% to -$2.8 million in 2022, then decreased by 4.02% to -$2.9 million in 2023, then skyrocketed by 1155.61% to $30.6 million in 2024, then increased by 0.04% to $30.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Revenue are $30.6 million (Q4 2025), $27.8 million (Q3 2025), and $28.2 million (Q2 2025).